Carolyn Vachani, RN, MSN, AOCN
Abramson Cancer Center of the University of Pennsylvania
Last Modified: March 23, 2007
The purpose of this prospective study was to address the efficacy of Yttrium ibritumomab tiuxetan (Zevalin) in patients with relapsed or refractory lymphomas who had already failed rituximab. Rituximab is a monocloncal antibody that targets CD20, which is found on the surface of lymphoma cells. Zevalin is rituximab with the addition of a radioactive molecule. The drug takes the radiation directly to the lymphoma cells, destroying it, but sparing the healthy tissues.
Twenty seven patients were enrolled, 22 with follicular lymphoma and 5 with Mantle cell lymphoma. All had previous treatments and five of the patients had previously undergone bone marrow transplant.
Tumor response was evaluated at 3 and 6 months after treatment. Fifteen patients responded to treatment, with eleven having a complete response and four having a partial response. Ten of eleven patients remained in remission for between 3 to 15 months. Toxicities were mostly related to myelosuppression (decreases in blood counts) and were treated with transfusions and growth factors. There was one treatment related death. There was a 41% complete response rate after treatment with Yttrium ibritumomab tiuxetan (Zevalin) in patients who had previously failed Rituximab. In addition, the drug appeared to be tolerated by patients who had previously undergone bone marrow transplant.
Dec 7, 2010 - Rituximab may be a better option than watchful waiting in some lymphoma patients, and a new treatment option appears effective for relapsed or refractory Hodgkin's lymphoma, according to two studies being presented at the annual meeting of the American Society of Hematology, held from Dec. 4 to 7 in Orlando, Fla. Other research being presented will highlight new options for the standard treatment of advanced asymptomatic follicular lymphoma; mantle cell lymphoma; and early, unfavorable Hodgkin's disease.
May 25, 2012
Mar 13, 2014
Jul 24, 2014